Mesenchymal Stem Cell Infusions for Children with ASD: Swiss Medica Research Study Results

Published 26 Jun 2024

1 min read

Updated 24 Oct 2024

We are glad to share the results of our recent research study on the safety and effectiveness of Mesenchymal stem cell (MSC) infusions for children with Autism Spectrum Disorders (ASD). It was conducted at the request of and in the interest of patients, and led by Dr. Lana Babinski, a pediatrician and specialist in regenerative medicine at Swiss Medica.

About the Research Study

The study conducted between January 2023 and May 2024 involved 30 children diagnosed with ASD, aged between 3 and 15 years. Each child received four units of cultivated allogeneic MSCs through intravenous and intramuscular injections. This was followed by a five-week course of MSC-derived exosomes that we delivered via nasal drops.

Unveiling the Key Findings

The MSC infusions were not only safe but also well-tolerated, with no serious adverse events reported. Among the 98 mild to moderate adverse events observed, the most common were agitation, fever, and aggression—none of which were serious or long-lasting. Importantly, there were no infusion-related infections or significant complications.

The nine-month assessment period yielded encouraging behavioral improvements:

1
Social Communication: 93.3% of participants initially struggled with verbal communication, but 90% showed improvements in verbal and nonverbal communication. Parents reported increased empathy, better use of gestures, and an expanded vocabulary.
2
Attention Span and Focus: Out of the 83.3% of children who had attention difficulties, 56% experienced significant enhancements in focus.
3
Cognitive Development: 80% of participants faced developmental delays, and 61.6% demonstrated marked improvements in learning and skill retention.
4
Hyperactivity and Aggression: These challenging symptoms improved in 66.7% of the children.

Overall, a 93.4% of participants saw significant improvement in at least one symptom, while 83.3% experienced improvements in half or more of their symptoms.

New Chapter in ASD Management

Given that ASD is a condition with no known cure, our objective wasn’t to completely fix all symptoms. However, our study provides some evidence that allogeneic MSC infusions are a safe and effective treatment that targets the core symptoms of ASD in children.

Given the positive outcomes of this study, we recommend continuing to use this MSC treatment protocol for children with ASD. Our commitment to advancing regenerative medicine and providing treatments for ASD symptoms remains strong.

For those eager to delve deeper into the full study and its results, we invite you to view the complete report. Please leave your email address below to receive a copy.